Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for myelodysplastic syndromes (MDS), yet conventional myeloablative conditioning is highly toxic in elderly or frail patients. Objectives: To compare a decitabine-based reduced-toxicity conditioning (RTC) regimen with modified BUCY in higher-risk MDS patients undergoing allo-HSCT in a real-world setting. Design: Single-center retrospective cohort study. Methods: We retrospectively analyzed 82 consecutive MDS patients undergoing first allo-HSCT between September 2022 and June 2025. Thirty-six patients received decitabine-based RTC (decitabine 20 mg/m 2 /day ×3 days with reduced-dose busulfan and fludarabine), while 46 received modified BUCY. End points were overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Results: The RTC group had higher baseline risks, including older age (median 57 vs. 53 years, P<0.01), higher HCT-CI scores (HCT-CI≥2: 44.4% vs. 10.9%, P<0.01), more prior debulking therapy (83% vs. 54%, P<0.01), and a trend for more TP53 mutations (22% vs. 13%, P=0.06). Despite greater frailty, 2-year outcomes were comparable: OS (80.5% vs. 75.1%, P=0.84), RFS (70.3% vs. 70.6%, P=0.79), CIR (13.5% vs. 9.6%, P=0.70), and NRM (16.1% vs. 22.0%, P=0.88). In multivariable models, the regimen was not significantly associated with OS (HR 0.35, 95% CI, 0.10–1.17; P=0.09), RFS (HR, 0.67; 95% CI, 0.23–1.92; P=0.45). HCT-CI ≥2 predicted higher mortality (HR, 6.32; 95% CI, 1.78–22.37; P=0.004). Conclusion: Despite the higher baseline frailty, decitabine-based RTC regimen achieved survival outcomes comparable to modified BUCY in MDS patients. These findings suggest its potential to expand transplant eligibility, warranting prospective studies.